Dorenem (Doripenem)

Gold standard” of monotherapy of serious infections in inpatient settings. Active against a wide range of gram-positive (+) and gram-negative aerobic bacteria, majority of anaerobic bacteria. Used in therapy of serious polymicrobic infections of lower respiratory tract, urinary system infections, intraabdominal infections, gynecological infections, skin and soft tissue infections, bone and joint infections, endocarditis.

An ultra-wide range of antibacterial activity includes practically all significant gram-positive (+) and gram-negative (-) aerobic and anaerobic microorganisms. Non-neurotoxic. Used for de-escalation therapy of serious infections of lower respiratory tract, intraabdominal infections, gynecological infections, skin and soft tissue infections, meningitis, septicemia, empiric treatment in patients with neutropenia, as monotherapy or in combination with antiviral or antifungal pharmaceutical products.

First antibiotic of the glycopeptide group. Highly active against a wide range of gram-positive (+) microorganisms, including methicillin-resistant strains. Used in treatment of endocarditis, sepsis, skin and soft tissue infections, bone and joint infections (including osteomyelitis), CNS infections (including meningitis), infections of lower respiratory tract, pseudomembranous colitis, enterocolitis.

The active ingredient of Claribaccin is clarithromycin. Clarithromycin is a semisynthetic macrolide antibiotic derived by substitution of CN3O hydroxyl group by (OH) group in the 6th position of the lactone ring of erythromycin, more precisely, clarithromycin is 6-Omethylerythromycin A. The mechanism of action of clarithromycin is based on binding to 50S ribosomal subunit of sensitive bacteria, which prevents the translocation of activated amino acids. Clarithromycin inhibits intracellular protein synthesis of microorganisms sensitive thereto and thereby exerts its antibacterial action.